OTCMKTS:TRSSF

TerrAscend Competitors

$9.95
-0.19 (-1.87 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.57
Now: $9.95
$10.47
50-Day Range
$9.28
MA: $10.94
$13.69
52-Week Range
$1.63
Now: $9.95
$16.25
Volume205,795 shs
Average Volume520,730 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

TerrAscend (OTCMKTS:TRSSF) Vs. ABAHF, ACRGF, APPB, AYRSF, CANB, and CNTMF

Should you be buying TRSSF stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to TerrAscend, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Can B (CANB), and Cansortium (CNTMF).

TerrAscend (OTCMKTS:TRSSF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Valuation and Earnings

This table compares TerrAscend and Abacus Health Products' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TerrAscendN/AN/AN/AN/AN/A
Abacus Health ProductsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for TerrAscend and Abacus Health Products, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TerrAscend00703.00
Abacus Health Products0000N/A

TerrAscend currently has a consensus target price of $18.5417, indicating a potential upside of 86.35%. Given TerrAscend's higher probable upside, research analysts plainly believe TerrAscend is more favorable than Abacus Health Products.

Profitability

This table compares TerrAscend and Abacus Health Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TerrAscendN/AN/AN/A
Abacus Health ProductsN/AN/AN/A

Summary

TerrAscend beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

Acreage (OTCMKTS:ACRGF) and TerrAscend (OTCMKTS:TRSSF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Valuation & Earnings

This table compares Acreage and TerrAscend's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcreageN/AN/AN/AN/AN/A
TerrAscendN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Acreage and TerrAscend, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acreage01202.67
TerrAscend00703.00

Acreage currently has a consensus price target of $8.4333, indicating a potential upside of 204.45%. TerrAscend has a consensus price target of $18.5417, indicating a potential upside of 86.35%. Given Acreage's higher possible upside, equities research analysts plainly believe Acreage is more favorable than TerrAscend.

Profitability

This table compares Acreage and TerrAscend's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcreageN/AN/AN/A
TerrAscendN/AN/AN/A

Summary

TerrAscend beats Acreage on 2 of the 3 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and TerrAscend (OTCMKTS:TRSSF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings for Applied Biosciences and TerrAscend, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Biosciences0000N/A
TerrAscend00703.00

TerrAscend has a consensus price target of $18.5417, suggesting a potential upside of 86.35%. Given TerrAscend's higher probable upside, analysts clearly believe TerrAscend is more favorable than Applied Biosciences.

Earnings and Valuation

This table compares Applied Biosciences and TerrAscend's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied BiosciencesN/AN/AN/AN/AN/A
TerrAscendN/AN/AN/AN/AN/A

Profitability

This table compares Applied Biosciences and TerrAscend's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied BiosciencesN/AN/AN/A
TerrAscendN/AN/AN/A

Summary

TerrAscend beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and TerrAscend (OTCMKTS:TRSSF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Ayr Strategies and TerrAscend's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayr StrategiesN/AN/AN/AN/AN/A
TerrAscendN/AN/AN/AN/AN/A

Profitability

This table compares Ayr Strategies and TerrAscend's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayr StrategiesN/AN/AN/A
TerrAscendN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Ayr Strategies and TerrAscend, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayr Strategies01602.86
TerrAscend00703.00

Ayr Strategies currently has a consensus target price of $34.8571, suggesting a potential upside of 63.96%. TerrAscend has a consensus target price of $18.5417, suggesting a potential upside of 86.35%. Given TerrAscend's stronger consensus rating and higher possible upside, analysts plainly believe TerrAscend is more favorable than Ayr Strategies.

Summary

TerrAscend beats Ayr Strategies on 3 of the 3 factors compared between the two stocks.

TerrAscend (OTCMKTS:TRSSF) and Can B (NASDAQ:CANB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Valuation & Earnings

This table compares TerrAscend and Can B's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TerrAscendN/AN/AN/AN/AN/A
Can BN/AN/AN/AN/AN/A

Profitability

This table compares TerrAscend and Can B's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TerrAscendN/AN/AN/A
Can BN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for TerrAscend and Can B, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TerrAscend00703.00
Can B0000N/A

TerrAscend presently has a consensus price target of $18.5417, indicating a potential upside of 86.35%. Given TerrAscend's higher probable upside, equities analysts clearly believe TerrAscend is more favorable than Can B.

Summary

TerrAscend beats Can B on 2 of the 2 factors compared between the two stocks.

TerrAscend (OTCMKTS:TRSSF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Valuation & Earnings

This table compares TerrAscend and Cansortium's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TerrAscendN/AN/AN/AN/AN/A
CansortiumN/AN/AN/AN/AN/A

Profitability

This table compares TerrAscend and Cansortium's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TerrAscendN/AN/AN/A
CansortiumN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for TerrAscend and Cansortium, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TerrAscend00703.00
Cansortium00103.00

TerrAscend presently has a consensus price target of $18.5417, indicating a potential upside of 86.35%. Cansortium has a consensus price target of $1.20, indicating a potential upside of 6.10%. Given TerrAscend's higher probable upside, equities analysts clearly believe TerrAscend is more favorable than Cansortium.

Summary

TerrAscend beats Cansortium on 2 of the 2 factors compared between the two stocks.


TerrAscend Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABAHF
Abacus Health Products
0.4$4.84-5.4%$0.00N/A0.00News Coverage
Gap Up
Acreage logo
ACRGF
Acreage
1.2$2.77-0.0%$0.00N/A0.00
Applied Biosciences logo
APPB
Applied Biosciences
0.5$0.21-81.0%$0.00N/A0.00Increase in Short Interest
Gap Up
AYRSF
Ayr Strategies
1.4$21.26-0.0%$0.00N/A0.00
Can B logo
CANB
Can B
0.4$0.52-3.9%$0.00N/A0.00Gap Down
Cansortium logo
CNTMF
Cansortium
0.7$1.13-4.4%$0.00N/A0.00Gap Down
Charlotte's Web logo
CWBHF
Charlotte's Web
1.3$3.90-2.8%$0.00N/A0.00
Choom logo
CHOOF
Choom
0.5$0.09-0.0%$0.00N/A0.00Gap Down
CPHRF
Cipher Pharmaceuticals
1.2$1.07-0.0%$0.00N/A0.00
CLS Holdings USA logo
CLSH
CLS Holdings USA
0.7$0.20-15.0%$0.00N/A0.00News Coverage
Gap Up
Cosmos logo
COSM
Cosmos
0.5$6.30-8.7%$0.00N/A0.00High Trading Volume
Increase in Short Interest
Gap Down
Cresco Labs logo
CRLBF
Cresco Labs
1.3$11.25-6.5%$0.00N/A0.00
Curaleaf logo
CURLF
Curaleaf
1.6$12.77-2.5%$0.00N/A0.00
HMDEF
DionyMed Brands
0.5N/AN/A$0.00N/A0.00High Trading Volume
Easton Pharmaceuticals logo
EAPH
Easton Pharmaceuticals
0.5$0.00-0.0%$0.00N/A0.00Gap Down
Elixinol Global logo
ELLXF
Elixinol Global
0.8$0.15-0.0%$0.00N/A0.00
EVIO logo
EVIO
EVIO
0.6$0.00-0.0%$0.00N/A0.00Gap Up
Flower One logo
FLOOF
Flower One
0.4$0.19-15.5%$0.00N/A0.00Gap Up
Golden Leaf logo
GLDFF
Golden Leaf
0.5$0.05-0.0%$0.00N/A0.00Gap Up
Green Growth Brands logo
GGBXF
Green Growth Brands
0.4$0.01-0.0%$0.00N/A0.00
Green Thumb Industries logo
GTBIF
Green Thumb Industries
1.7$26.82-1.2%$0.00N/A0.00Gap Down
GTEC logo
GGTTF
GTEC
0.6$0.57-7.0%$0.00N/A0.00Gap Up
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$2.85-0.7%$0.00N/A0.00Gap Up
Hemp Naturals logo
HPMM
Hemp Naturals
0.6$0.01-0.0%$0.00N/A0.00
Hexo logo
HYYDF
Hexo
0.6N/AN/A$0.00N/A0.00
Hikma Pharmaceuticals logo
HKMPY
Hikma Pharmaceuticals
0.4$65.83-10.3%$0.00N/A0.00Gap Down
iAnthus Capital logo
ITHUF
iAnthus Capital
0.6$0.18-5.6%$0.00N/A0.00Gap Up
Icanic Brands logo
ICNAF
Icanic Brands
0.6$0.27-3.7%$0.00N/A0.00Gap Up
KNHBF
ICC International Cannabis
0.6N/AN/A$0.00N/A0.00
Invictus MD Strategies logo
IVITF
Invictus MD Strategies
0.6$0.04-0.0%$0.00N/A0.00
Isodiol International logo
ISOLF
Isodiol International
0.4$0.06-0.0%$0.00N/A0.00Gap Down
Khiron Life Sciences logo
KHRNF
Khiron Life Sciences
1.4$0.38-10.6%$0.00N/A0.00Gap Up
KHTRF
Knight Therapeutics
1.2$4.15-0.7%$0.00N/A0.00
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01-0.0%$0.00N/A0.00Gap Down
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.05-0.0%$0.00N/A0.00News Coverage
Gap Down
MediPharm Labs logo
MEDIF
MediPharm Labs
1.2$0.37-0.0%$0.00N/A0.00Increase in Short Interest
MedMen Enterprises logo
MMNFF
MedMen Enterprises
0.8$0.26-7.7%$0.00N/A0.00Gap Down
MERCK Kommanditgesellschaft auf Aktien logo
MKKGY
MERCK Kommanditgesellschaft auf Aktien
0.5$35.05-1.3%$0.00N/A0.00Increase in Short Interest
MJardin Group logo
MJARF
MJardin Group
1.1$0.06-16.7%$0.00N/A0.00
MYHI
Mountain High Acquisitions
0.5$0.02-0.0%$0.00N/A0.00Gap Up
PHCEF
Pharmacielo
0.7$1.34-6.7%$0.00N/A0.00Gap Up
Plus Products logo
PLPRF
Plus Products
1.1$0.51-2.0%$0.00N/A0.00Gap Down
Premier Biomedical logo
BIEI
Premier Biomedical
0.5$0.00-0.0%$0.00N/A0.00Gap Up
PCYN
Procyon
0.4$0.60-0.0%$0.00N/A0.00
Pure Global Cannabis logo
PRCNF
Pure Global Cannabis
0.7$0.01-0.0%$0.00N/A0.00
SANP
Santo Mining
0.5$0.00-0.0%$0.00N/A0.00
Shionogi & Co., Ltd. logo
SGIOY
Shionogi & Co., Ltd.
0.5$12.76-2.1%$0.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
DNPUF
Sumitomo Dainippon Pharma
0.5$17.40-0.0%$0.00N/A0.00News Coverage
The Flowr logo
FLWPF
The Flowr
1.5$0.22-4.5%$0.00N/A0.00Gap Up
The Supreme Cannabis logo
SPRWF
The Supreme Cannabis
1.2$0.28-7.2%$0.00N/A0.00
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.